Outcomes of newly diagnosed multiple myeloma with deferred ASCT after achieving ≥VGPR following PAD induction in the Phase 2 PADIMAC study
Wei Yee Chan(Royal London Hospital), Kwee Yong(CRUK Lung Cancer Centre of Excellence), Neil Rabin(University College London), Claire Roddie(Cancer Institute (WIA)), Steve Schey(King's College London), Elizabeth H. Phillips(University of Manchester), Nicholas Counsell(University College London), Mickey Koh(St George's Hospital), Gordon Cook(University of Leeds), Laura Clifton‐Hadley(Cancer Research UK), Guy Pratt(University Hospitals Birmingham NHS Foundation Trust), Toyin Adedayo(Cancer Research UK), Mark Cook(Université Paris Cité), Matthew Streetly(King's College - North Carolina), Curly Morris(Belfast Health and Social Care Trust), Roger G. Owen(Leeds Teaching Hospitals NHS Trust), Dunnya De‐Silva(University of Liverpool), Rakesh Popat(University College London Hospitals NHS Foundation Trust), Ruth de Tute(Leeds Teaching Hospitals NHS Trust), Josephine Crowe(Royal United Hospital), Andres Virchis(The Royal Free Hospital), Michael Quinn(University of Ulster), Charles Crawley(Addenbrooke's Hospital), Nivette Braganca(Cancer Research UK), Jamie Cavenagh(St Bartholomew's Hospital), Shirley D’Sa(University College Hospital)
Cited by 0
Related Papers
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
|New England Journal of Medicine|2003|1.8k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
Guidelines for the diagnosis and management of adult aplastic anaemia
|British Journal of Haematology|2015|750
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
|New England Journal of Medicine|2023|695